Michael Moore: Going Beyond ‘HMO’s Suck’
The guerrilla documentary filmmaker's next movie, "Sicko," will be "a comedy about 45 million people with no health care in the richest country on earth." But it's not just "a movie that tells you that HMOs and the pharmaceutical companies suck. Everybody knows that. I'd like to show you some things you don't know."The guerrilla documentary filmmaker’s next movie, “Sicko” will be “a comedy about 45 million people with no health care in the richest country on earth.” But it’s not just “a movie that tells you that HMOs and the pharmaceutical companies suck. Everybody knows that. I’d like to show you some things you don’t know.”
Your support matters…Michael Moore:
We’ve spent the better part of this year shooting our next movie, “Sicko.” As we’ve done with our other films, we don’t discuss them while we are making them. If people ask, we tell them “Sicko” is “a comedy about 45 million people with no health care in the richest country on earth.”
But like my other movies, what we start with (General Motors, guns, 9/11) is not always what we end with. Along the way, we discover new roads to go down, roads that often surprise us and lead us to new ideas — and challenge us to reconsider the ones we began with. That, I can say with certainty, is happening now as we shoot “Sicko.” I don’t think the country needs a movie that tells you that HMOs and the pharmaceutical companies suck. Everybody knows that. I’d like to show you some things you don’t know. So stay tuned for where this movie has led me. I think you might enjoy it.
Independent journalism is under threat and overshadowed by heavily funded mainstream media.
You can help level the playing field. Become a member.
Your tax-deductible contribution keeps us digging beneath the headlines to give you thought-provoking, investigative reporting and analysis that unearths what's really happening- without compromise.
Give today to support our courageous, independent journalists.
You need to be a supporter to comment.
There are currently no responses to this article.
Be the first to respond.